After Withdrawing IPO, Fluidigm Reaffirms Plan to Go Public Once Markets Stabilize | GenomeWeb
Volatility in the US credit and equity markets forced biochip maker Fluidigm earlier this month to postpone indefinitely its plan for an initial public offering, though a re-attempt could happen sometime in 2009, according to a company official.
 
Fluidigm spokesperson Howard High said this week that the timing of a re-attempt is “up in the air,” and that the company will “wait for the US financial markets to settle down.”
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.